Item 5.02 Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers.
On April 22, 2020, the Board of Directors of Exact Sciences Corporation (the
"Company") appointed Freda Lewis-Hall, M.D., DFAPA to serve as a Class II
director until the 2020 Annual Meeting of Stockholders.
Dr. Lewis-Hall served as Chief Patient Officer and Executive Vice President of
Pfizer Inc. (NYSE: PFE) from January 2019 to December 2019. She acted as a
Senior Medical Advisor to the CEO until her retirement in March 2020. From 2009
to December 2019, Dr. Lewis-Hall served as Pfizer's Chief Medical Officer and
Executive Vice President. Prior to joining Pfizer in 2009, Dr. Lewis-Hall held
various senior leadership positions including Chief Medical Officer and
Executive Vice President, Medicines Development at Vertex Pharmaceuticals, Inc.,
a biopharmaceutical company, from 2008 to 2009, and Senior Vice President, U.S.
Pharmaceuticals, Medical Affairs for Bristol-Myers Squibb Co. from 2003 to 2008.
Dr. Lewis-Hall serves on the board of directors of SpringWorks Therapeutics,
Inc. (NASDAQ: SWTX) and 1Life Healthcare, Inc. (NASDAQ: ONEM). From December
2014 to May 2017, she served on the board of directors of Tenet Healthcare
Corporation (NYSE: THC). Dr. Lewis-Hall currently serves on the board of fellows
of The Harvard School and the board of advisors of the Dell Medical School. She
also serves as a member of the board of governors for the Patient-Centered
Outcomes Research Institute. Dr. Lewis-Hall earned a B.A. in Natural Sciences
from Johns Hopkins University and an M.D. from Howard University College of
Dr. Lewis-Hall will receive compensation for her service as a director in
accordance with the Company's Non-Employee Director Compensation Policy filed
herewith as Exhibit 10.1 and incorporated herein by reference (the "Director
Compensation Policy"). Pursuant to the Non-Employee Director Compensation
Policy, in connection with her initial appointment to the Board of Directors,
Dr. Lewis-Hall received a stock award valued at $375,000.
9.01. Financial Statements and Exhibits.
The following exhibit is filed herewith:
Exhibit No. Exhibit Description
10.1 Non-Employee Director Compensation Policy dated April 22, 2020.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
© Edgar Online, source Glimpses